The present invention includes a method of inhibiting, suppressing or preventing HBV infection in an individual in need thereof, comprising administering to the individual a therapeutically effective amount of at least one compound of the invention.

Compounds of the formula (I), (Ia) or (Ib) wherein A.sub.1, and A.sup. is for example (II) is 1 or 2; X is C.sub.1-C.sub.4 alkylene or CO; Y is for example O, O(CO), O(CO)O, R.sub.1 is for example hydrogen, d-dsalkyl, C.sub.3-C.sub.30cycloalkyl, phenyl, naphthyl, anthracyl, phenanthryl, biphenylyl, fluorenyl or C.sub.3-C.sub.20heteroaryl, all of which optionally are substituted; R.sub.2 and R.sub.3 for example are C.sub.1-C.sub.10haloalkylene which is optionally substituted, or R.sub.2 and R.sub.3 are phenylene, which optionally is substituted; R.sub.4 is a group (A) or a group (B); R.sub.5 and R.sub.6 for example are C.sub.1-C.sub.20alkyl; or R.sub.4 and R.sub.5 or R.sub.4 and R.sub.6 together form a straight-chain C.sub.2-C.sub.6alkylene, R.sub.5 and R.sub.6 together form a straight-chain C.sub.2-C.sub.6alkylene; R.sub.7, R.sub.8, R.sub.9 and R.sub.10 ifor example are C.sub.1-C.sub.20alkyl; M for example is C.sub.1-C.sub.20alkylene, C.sub.2-C.sub.20alkenylene, C.sub.2-C.sub.20alkynylene; R.sub.25 and R.sub.26 are for example hydrogen, C.sub.1-C.sub.20alkyl; R.sub.27, R.sub.28, R.sub.29, R.sub.30 and R.sub.31 are for example hydrogen, C.sub.1-C.sub.20alkyl, C.sub.2-C.sub.20alkenyl, C.sub.3-C.sub.20cycloalkyl, or two radicals R.sub.27 and R.sub.28, R.sub.28 and R.sub.29, R.sub.29 and R.sub.30 and/or R.sub.30 and R.sub.31 together form a straight-chain C.sub.2-C.sub.6alkylene, or R.sub.25 and R.sub.27 together form 1,2-phenylene, R.sub.33 and R.sub.34 for example are hydrogen, C.sub.1-C.sub.20alkyl; R.sub.35, R.sub.36 and R.sub.37 for example are hydrogen, C.sub.1-C.sub.20alkyl; are suitable as thermo-acid generators. ##STR00001##

Compounds of the formula (I), (Ia) or (Ib) wherein A.sub.1, and A.sup. is for example (II) is 1 or 2; X is C.sub.1-C.sub.4 alkylene or CO; Y is for example O, O(CO), O(CO)O, R.sub.1 is for example hydrogen, d-dsalkyl, C.sub.3-C.sub.30cycloalkyl, phenyl, naphthyl, anthracyl, phenanthryl, biphenylyl, fluorenyl or C.sub.3-C.sub.20heteroaryl, all of which optionally are substituted; R.sub.2 and R.sub.3 for example are C.sub.1-C.sub.10haloalkylene which is optionally substituted, or R.sub.2 and R.sub.3 are phenylene, which optionally is substituted; R.sub.4 is a group (A) or a group (B); R.sub.5 and R.sub.6 for example are C.sub.1-C.sub.20alkyl; or R.sub.4 and R.sub.5 or R.sub.4 and R.sub.6 together form a straight-chain C.sub.2-C.sub.6alkylene, R.sub.5 and R.sub.6 together form a straight-chain C.sub.2-C.sub.6alkylene; R.sub.7, R.sub.8, R.sub.9 and R.sub.10 ifor example are C.sub.1-C.sub.20alkyl; M for example is C.sub.1-C.sub.20alkylene, C.sub.2-C.sub.20alkenylene, C.sub.2-C.sub.20alkynylene; R.sub.25 and R.sub.26 are for example hydrogen, C.sub.1-C.sub.20alkyl; R.sub.27, R.sub.28, R.sub.29, R.sub.30 and R.sub.31 are for example hydrogen, C.sub.1-C.sub.20alkyl, C.sub.2-C.sub.20alkenyl, C.sub.3-C.sub.20cycloalkyl, or two radicals R.sub.27 and R.sub.28, R.sub.28 and R.sub.29, R.sub.29 and R.sub.30 and/or R.sub.30 and R.sub.31 together form a straight-chain C.sub.2-C.sub.6alkylene, or R.sub.25 and R.sub.27 together form 1,2-phenylene, R.sub.33 and R.sub.34 for example are hydrogen, C.sub.1-C.sub.20alkyl; R.sub.35, R.sub.36 and R.sub.37 for example are hydrogen, C.sub.1-C.sub.20alkyl; are suitable as thermo-acid generators. ##STR00001##

The present invention includes a method of inhibiting, suppressing or preventing HBV infection in an individual in need thereof, comprising administering to the individual a therapeutically effective amount of at least one compound of the invention.

2MeTHF is expected to be used to develop poly(tetramethylene ether) glycol as a bio-urethane material, which has new performance with excellent chemical and mechanical properties. The purpose is to provide poly(tetramethylene ether) glycol that does not cause coloration and its production method so that its value as an industrial raw material is not reduced. Poly(tetramethylene ether) glycol which is a copolymerization reaction product of tetrahydrofuran and plant-derived 2-methyltetrahydrofuran, wherein the 2-methyltetrahydrofuran is 2-methyltetrahydrofuran purified by a purification step that includes contacting the 2-methyltetrahydrofuran with an acid.

2MeTHF is expected to be used to develop poly(tetramethylene ether) glycol as a bio-urethane material, which has new performance with excellent chemical and mechanical properties. The purpose is to provide poly(tetramethylene ether) glycol that does not cause coloration and its production method so that its value as an industrial raw material is not reduced. Poly(tetramethylene ether) glycol which is a copolymerization reaction product of tetrahydrofuran and plant-derived 2-methyltetrahydrofuran, wherein the 2-methyltetrahydrofuran is 2-methyltetrahydrofuran purified by a purification step that includes contacting the 2-methyltetrahydrofuran with an acid.

The application relates to a compound of Formula (I) or (I):

##STR00001##

or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, which modulates the activity of SSAO, a pharmaceutical composition comprising a compound of Formula (I) or (I), and a method of treating or preventing a disease in which SSAO plays a role.

An object of the present disclosure is to provide a method for producing an organic compound, and a composition. The object is achieved by a method for producing a compound represented by formula (1): ##STR00001## wherein X represents O, an optionally substituted imino group, or S, R.sup.1 represents a hydrogen atom or a hydrocarbyl group optionally having at least one substituent, and R.sup.2 represents a hydrogen atom or a monovalent organic group, or R.sup.1 and R.sup.2, together with X and one carbon atom respectively adjacent to R.sup.1 and R.sup.2, may form a heterocyclic ring optionally having at least one substituent, R.sup.3 represents a hydrogen atom or a monovalent organic group, and R.sup.4 represents CF.sub.2CH.sub.3 or CH.sub.2CHF.sub.2; the method including step A of reacting a compound represented by formula (2): ##STR00002## wherein the alphabetical symbols are as defined above, with vinylidene fluoride under light irradiation.

An object of the present disclosure is to provide a method for producing an organic compound, and a composition. The object is achieved by a method for producing a compound represented by formula (1): ##STR00001## wherein X represents O, an optionally substituted imino group, or S, R.sup.1 represents a hydrogen atom or a hydrocarbyl group optionally having at least one substituent, and R.sup.2 represents a hydrogen atom or a monovalent organic group, or R.sup.1 and R.sup.2, together with X and one carbon atom respectively adjacent to R.sup.1 and R.sup.2, may form a heterocyclic ring optionally having at least one substituent, R.sup.3 represents a hydrogen atom or a monovalent organic group, and R.sup.4 represents CF.sub.2CH.sub.3 or CH.sub.2CHF.sub.2; the method including step A of reacting a compound represented by formula (2): ##STR00002## wherein the alphabetical symbols are as defined above, with vinylidene fluoride under light irradiation.